Walgreens Boots Alliance, Inc.

As of March 28, 2024, Walgreens Boots Alliance is considered risky and overvalued due to a negative P/E ratio, low ROE of -9.46%, and unfavorable valuation metrics, despite a recent 1-year return of 29.51% that outperformed the S&P 500, while suffering a significant 5-year decline of -69.09%.

As of March 28, 2024, Walgreens Boots Alliance is considered overvalued and risky due to significant financial challenges, a negative return on equity of -9.46%, and poor stock performance, contrasting unfavorably with peers like AbbVie and Merck.

As of June 9, 2025, Walgreens Boots Alliance, Inc. shows a bullish technical trend supported by a positive weekly MACD and daily moving averages, despite some mixed signals from Bollinger Bands and a mildly bearish weekly KST.

As of March 2022, the management team of Walgreens Boots Alliance, Inc. includes Executive Chairman James Skinner, CEO Stefano Pessina, Lead Independent Director William Foote, and several Independent Directors: Jose Almeida, Janice Babiak, David Brailer, and Ginger Graham. They oversee the company's strategic direction and operations.

Walgreens Boots Alliance, Inc. is a pharmacy-led health and wellbeing holding company with a market cap of approximately $13.37 billion, reporting net sales of $38.59 billion and a net loss of $4.04 billion as of February 2025. Key metrics include a dividend yield of 322.73% and a debt-to-equity ratio of 1.32.

As of Jun 18, Walgreens Boots Alliance, Inc. has a market capitalization of 13,374.50 million, with net sales of 151,945.00 million and a net profit of -7,489.00 million over the latest four quarters. As of Aug 24, the company reported shareholder's funds of 10,445.00 million and total assets of 81,037.00 million.